Proactive Investors - Run By Investors For Investors

MaxCyte inks research agreement with Gilead subsidiary Kite Pharma

The AIM-listed bioscience firm said under the agreement Kite would use its Flow Electroporation Technology platform to enable non-viral cell engineering
Cell being injected
Flow Electroporation is used in gene editing and allows almost any molecule to be delivered into a cell

MaxCyte Inc (LON:MXCT) has signed a research agreement with Kite Pharma Inc, a subsidiary of US drugmaker Gilead Sciences Inc (NASDAQ:GILD), to use its Flow Electroporation Technology (FET) platform.

The AIM-listed bioscience firm said under the agreement Kite would use the FET platform to enable non-viral cell engineering.

WATCH: Major announcements for MaxCyte

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

Doug Doerfler, president and chief executive of MaxCyte, said Kite would be utilising the firm’s platform to enable gene-editing technologies for the research and development of new therapeutics.

The deal follows a commercial license agreement signed last week between MaxCyte and gene-based medicine maker CRISPR Therapeutics in a move to advance the development of anti-cancer treatments.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Related Articles

tablets and pills
July 16 2019
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use